Aslani Mohammad Reza, Ghobadi Hassan, Sarikhani Khadijeh, Hosseininia Saeid, Sadeghieh-Ahari Saeid
Lung Inflammatory Diseases Research Center, Department of Physiology, Ardabil University of Medical Sciences, Ardabil, Iran.
Department of Internal Medicine (Pulmonary Division), School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Tanaffos. 2020 Jul;19(3):208-215.
The present study was done to compare serum heart type-fatty acid-binding protein (H-FABP) levels in patients with stable chronic obstructive pulmonary disease (COPD) and healthy subjects and address the correlation of this marker with airflow limitation and health-related quality of life using the COPD assessment test (CAT).
In this cross-sectional study, we measured serum H-FABP levels in 50 patients with stable COPD and 34 healthy controls and compared them in terms of smoking history, airflow limitation according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and CAT score. We also tested the association between serum H-FABP level and the COPD patients' clinical parameters. For statistical analysis, we used the Student's t-test, ANOVA, and Pearson's (or Spearman's rank -order) correlation test.
Serum H-FABP level increased in the COPD patients compared with the control group (<0.01). Although there was no association between serum H-FABP levels and disease severity based on the GOLD criteria, FABP levels increased in the subjects with a history of smoking in compared with the non-smoker control subjects (< 0.01). In addition, there was a significant positive correlation between serum H-FABP level and smoking history (r = 0.367, P = 0.001).
The serum H-FABP level increased in both the stable COPD patients and healthy subjects with smoking history. However, no correlation was found between serum H-FABP and the severity of airflow limitation based on the GOLD criteria. Based on the results, it is unclear whether the H-FABP level is a causative factor in COPD patients or healthy smokers.
本研究旨在比较稳定期慢性阻塞性肺疾病（COPD）患者与健康受试者血清心脏型脂肪酸结合蛋白（H-FABP）水平，并使用慢性阻塞性肺疾病评估测试（CAT）探讨该标志物与气流受限及健康相关生活质量的相关性。
在这项横断面研究中，我们测量了50例稳定期COPD患者和34名健康对照者的血清H-FABP水平，并根据吸烟史、按照慢性阻塞性肺疾病全球倡议（GOLD）标准的气流受限情况以及CAT评分进行比较。我们还测试了血清H-FABP水平与COPD患者临床参数之间的关联。进行统计分析时，我们使用了学生t检验、方差分析以及Pearson（或Spearman等级）相关检验。
与对照组相比，COPD患者血清H-FABP水平升高（P<0.01）。尽管根据GOLD标准血清H-FABP水平与疾病严重程度之间无关联，但与非吸烟对照受试者相比，有吸烟史的受试者FABP水平升高（P<0.01）。此外，血清H-FABP水平与吸烟史之间存在显著正相关（r = 0.367，P = 0.001）。
稳定期COPD患者和有吸烟史的健康受试者血清H-FABP水平均升高。然而，根据GOLD标准，未发现血清H-FABP与气流受限严重程度之间存在相关性。基于这些结果，尚不清楚H-FABP水平在COPD患者或健康吸烟者中是否为致病因素。
